Indikation: Ovarial-, Tuben-, Peritoneal­kar­zinom

Erstlinie:

Bevacizumab (epithelial, fortgeschritten)

 

Folgelinien:

Bevacizumab (epithelial, anti-VEGF-naiv)
Niraparib (high-grade serös, Pt-sensitiv)
Olaparib (high-grade serös, Pt-sensitiv; fortgeschritten, high-grade epithelial, BRCA1/2- mt, HRD+, nach Pt-CT und Bevacizumab:
+ Bevacizumab)
Rucaparib (high-grade epithelial, [BRCA-Mt], Pt-sensitiv)